Study identifier:D4191C00137
ClinicalTrials.gov identifier:NCT05303532
EudraCT identifier:2021-003031-29
CTIS identifier:2023-507337-22-00
ROSY-D: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
cancer
Phase 3
No
Durvalumab
All
61
Interventional
18 Years - 99 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Nov 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Durvalumab Participants will receive durvalumab. | - |